Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lengthening Adalimumab Dosing Interval in IBD Patients in Long-term Remission
2014-001919-39Phase 4Active
- Sponsor
- Erasmus MC
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary: Non-inferiority in HBI and SCCAI scores. Started May 2014; status: active.
02
Drugs
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2014-001919-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001919-39.